ArticleAmerican journal of hematology2010
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Article in American journal of hematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- Cardiac Toxicity in the Treatment of Light Chain Amyloidosis: Systematic Review of Clinical Studies.Current drug safety · 2024Pooled it
- A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.Leukemia · 2022Trial
- Trial
- Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.Haematologica · 2013Trial
- A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.Haematologica · 2013Trial
- Trial
- Trial
- Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosis.British journal of haematology · 2025Article
- Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement.Blood research · 2023Article
- Natriuretic Peptides and Cardiac Troponins: Markers of Disease Progression and Risk in Light Chain Cardiac Amyloidosis.Current heart failure reports · 2023Review
- Diagnosis and Treatment of AL Amyloidosis.Drugs · 2023Review
- Cardiovascular toxicity from therapies for light chain amyloidosis.Frontiers in cardiovascular medicine · 2023Review
- Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis.Therapeutics and clinical risk management · 2023Review
- Vector autoregression: Useful in rare diseases?-Predicting organ response patterns in a rare case of secondary AA amyloidosis.PloS one · 2023Article
- Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist.Internal and emergency medicine · 2022Review
- Cardiac Amyloidosis Treatment.Methodist DeBakey cardiovascular journal · 2022Review
- Biomarkers in AL Amyloidosis.International journal of molecular sciences · 2021Review
- Progressive and atypical neurological symptoms in refractory systemic AL amyloidosis.Internal and emergency medicine · 2021Article
- AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies:JACC. CardioOncology · 2021Review
- Current Updates on the Management of AL Amyloidosis.Journal of hematology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
We evaluated the capability of soluble cardiac biomarkers to predict tolerability and outcomes of IMiD-containing treatments among 106 patients treated on clinical trials. Baseline elevations in troponin T (TnT) and N-terminal brain naturietic protein (NT-proBNP) predicted for an inability to tolerate IMiD-based regimens. The best predictors for early attrition during cycle 1 were TnT ≥ 0.07 μg/L and NT-proBNP ≥ 11,939 ng/L. NT-proBNP-response underperformed TnT-response as a predictor for overall survival (OS), but both predicted for early protocol attrition. Despite hematologic response, IMiD-treated patients were at higher risk for NT-proBNP rises and early drug discontinuation than a control population but not for early death. These observations prompt two questions: (1) does IMiD-based therapy lead to increased fluid retention and/or cardiac toxicity and (2) is an NT-proBNP-driven cardiac response system valid in IMiD-treated amyloidosis patients? Recognition of potential drug-induced cardiac toxicity is important so that increased cardiac surveillance and drug dose-adjustment or discontinuation may be implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.